Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy
Blackwell, K, Gascon, P, Krendyukov, A, Gattu, S, Li, Y, Harbeck, NLanguage:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdx638
Date:
October, 2017
File:
PDF, 298 KB
english, 2017